| Table 2: Fresh embryo transfer and freeze-all cycle mean costs – cost analysis from the perspective of our private center policy and charges – Scenario 1 | |||
|
FRESH (n=351) |
FREEZE-ALL (n=179) |
P | |
| ICSI cycle | 3,618.50 | 3,618.50 | – |
| rFSH | 2,293.65±692.38 | 2,123.72±644.47 | 0.006 |
| GnRH antagonist | 480.24±73.58 | 479.15±75.53 | 0.874 |
| Trigger | 111.63 | 111.63 | NA |
| LPS | 268.98±192.31 | – | NA |
| EP + LPS | – | 377.30±211.29 | NA |
| Hormone measurements – COS | 111.28 | 111.28 | NA |
| Hormone measurements – FET | – | 30.61±8.39 | NA |
| US scan – FET | – | 72.72±19.93 | NA |
| US – obstetrics | 84.57±106.26 | 104.29±109.02 | 0.046 |
| Embryo cryopreservation | 416.32±381.59 | 521.45±357.43 | 0.002 |
| Miscarriage cost | 38.59±161.54 | 47.49±178.79 | 0.550 |
| Total treatment cost per patient | 7,423.79±755.59 | 7,598.48±686.47 | 0.010 |
| Treatment cost per ongoing pregnancy | 23,059.72±2,347.02 | 19,156.73±1,732.99 | 0.001 |
* Values are expressed as the mean ± SD, or only the mean when all patients in the group had the same costs; the costs are in USD.
rFSH – recombinant follicle-stimulating hormone; GnRH – gonadotropin-releasing hormone; LPS – luteal phase support; EP – endometrial priming; COS – controlled ovarian stimulation; FET – frozen-thawed embryo transfer; US – ultrasound